BPC-157 works primarily through angiogenesis promotion and nitric oxide system modulation, while TB-500 (thymosin beta-4) operates through actin sequestration and cell migration facilitation
Link Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D
Routes Subcutaneous (SubQ) injection and topical formulations are the two main research-use routes
This modification renders the peptide resistant to enzymatic degradation, significantly extending its half-life and potency in vivo compared to standard L-peptides
Current Evidence for Efficacy Preclinical Studies The majority of evidence supporting the therapeutic efficacy of BPC-157 and TB-500 derives from extensive preclinical investigations conducted in various experimental models
Im not here to make decisions for people, says Meakins